Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio This imho is more important than StemPrintER. They want to cash in StemprintER ,
Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.